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All the sleep-promoting substances currently identified also have other biological activities.
Despite yearsofeffort, asinglespecificcentralnervoussystemsleepcenterhasnot beendescribed.
These observations led us to propose a biochemical model ofa sleep activational system in which
the effects of several sleep factors are integrated into a regulatory scheme. These sleep factors
interact by altering the metabolism, production, or activity of each other and thereby result in
multiple feedback loops. This web ofinteractions leads to sleep stability in that minor challenges
to the system will not greatly alter sleep. The system, however, is responsive to strong perturba-
tions, such as sleep deprivation and infectious disease. The sleep-promoting effects of cytokines
andtheirinteractions with prostaglandins andtheneuroendocrine systemareusedtoillustratethe
functioning of a part of the sleep activational system under normal conditions and during
infectious disease. Although the actions of individual sleep factors are not specific to sleep, their
interactions at various levels ofthe neuraxis can mediate a specific sleep response. Such a system
would also be responsive to the autonomic and environmental parameters that alter sleep.
INTRODUCTION
The concept that sleep is regulated in part by humoral mechanisms is supported by
experimental demonstrations of somnogenic substances in tissue fluids (reviewed,
[1-4]). These experiments began at the turn ofthe century with Legendre and Pieron
[5] and Ishimori [6], whodescribed theaccumulation during prolonged wakefulness of
substances in cerebrospinal fluid (CSF) that induce excess sleep when transferred to
recipient animals. Although the chemical identity of these substances was never
established, today over 30 putative sleep factors (SFs) have been identified (reviewed,
[2]). Most ofthese putative SFs are hormones, immunomodulators, and/or substances
involved in endocrine and/or immune regulation.
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Until recently, it was postulated that a SF, herein defined as any substance found
within the body that alters sleep, would have biological actions specific to sleep and
would act on central nervous system (CNS) executive sleep centers, which were also
assumed to be concerned primarily with sleep regulation. A single CNS center
necessary for sleep has not, however, been demonstrated. Furthermore, all SFs
identified to date have multiple biological activities. Thus, a revision of the original
assumptions is necessary. This review describes a model that links the sleep effects of
many putative SFs in a sleep activational system.
The sleep activational system presented is fundamentally a biochemical model and,
like all models, is provisional; the cellular localization of many of the specific compo-
nents that are germane to sleep regulation is not known. Nevertheless, it is assumed
that specific components of the model ultimately interact with either glia and/or
neurons at various levels of the CNS and that such interactions lead to altered sleep.
We propose that such a system would be responsive to the many autonomic and
environmental parameters that influence sleep, yet would retain the capacity to
regulate sleep selectively.
Rapid-eye-movement sleep (REMS) and non-rapid-eye-movement sleep (NREMS)
are the two major types of sleep, although subdivisions of each of these classes have
been made. To identify these states ofvigilance, the electroencephalogram (EEG) and
other physiological measurements, e.g., electromyogram, brain temperature, and
motor activity, are recorded. REMS and NREMS states exist in most mammals. Sleep
in animals, however, is slightly different from that of humans. Thus, species often used
in sleep research, such as rats, cats, and rabbits, have sleep episodes that are relatively
short, typically lasting only for a few minutes. These bouts of sleep occur sporadically
throughout the 24-hour day, alternating with episodes of wakefulness, although the
percentage ofany given hour spent in sleep is strongly influenced by circadian rhythms.
PROMOTION OF SLEEP BY CYTOKINES
Attempts to identify a sleep-promoting substance accumulating in CSF during sleep
deprivation (FactorS) [7] resulted in the discovery of the somnogenic activity of
muramyl peptides [8]. The sleep-promoting muramyl peptide isolated from rabbit
brain and from human urine has biochemical characteristics similar to those of Factor
S obtained from CSF [9].
Muramyl peptides are monomeric building blocks of bacterial peptidoglycans and
are released during processing of bacterial cell walls by mammalian macrophages
[10,11 ]. Muramyl peptides, however, are not the only sleep-promoting substances that
can be obtained from microorganisms. Endotoxin and its lipid A moiety, components of
the cell wall of gram-negative bacteria, also promote NREMS [12,13]. In addition,
recent experiments show that a synthetic double-stranded RNA, polyriboinosinic:
polyribocytidylic acid (poly I:C) [14], and RNA extracted from influenza-infected
lungs are somnogenic [15].
Although the structure and nature of these sleep-promoting agents of microbial
origin are widely different, they have an important common feature: all of them
stimulate a set of systemic host defense reactions collectively termed the acute-phase
response. Manifestations of the acute-phase response include activation of the immune
system, changes in hormone secretion and hepatic synthesis of plasma proteins,
alterations in metabolism, and fever [16,17]. These changes are observed after
infections or tissue damage. Increased lassitude or sleepiness is a common experience
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during infectious diseases; these symptoms are regarded as part of the acute-phase
response. Recent studies, in fact, have produced experimental evidence for enhance-
ment ofsleep during bacterial [18] and fungal [19] infections. It seems, therefore, that
the somnogenic activities of muramyl peptides, endotoxin, or double-stranded RNA
are associated with the capacity of these substances to stimulate the acute-phase
response. This notion suggests that the mechanisms of the acute-phase response may
provide clues for understanding sleep regulation.
The acute-phase response is under humoral regulation. The bioactive substances
released from cells affected by infection, inflammation, or tissue damage reach a wide
range of target organs, including the CNS. Classical examples of inflammatory
mediators include histamine, prostaglandins, neuropeptides like substance P, hor-
mones (cortisol, growth hormone [GH], and the like), and well-known neuronal
transmitters like noradrenaline [16,17,20]. A special group of polypeptides, the
cytokines, has, however, fundamental importance in the mediation of the acute-phase
response. Muramyl peptides, endotoxin, and poly I:C are all well known for their
ability to induce cytokine production. Although production ofcytokines was formerly
attributed to leukocytes, it has now beenestablished that at least somecytokines can be
released from a wide variety of cells [16] and that cytokines may act as general
intercellular communication signals. The number of identified cytokines increases
continuously, and interactions among cytokines are complicated and poorly under-
stood. Some seem to act in parallel, whereas others may be involved in a cascade-like
process or may inhibit each other [17,21]. The amount ofindividual cytokines released
varies with thespecific noxious agent [22], and this fact may be reflected by differences
of the clinical symptoms of the acute-phase response. Nevertheless, one of the
cytokines, interleukin 1 (IL-1), seems to have an essential role in the mediation ofthe
acute-phase response. Administration of IL-I elicits all of the studied clinical and
laboratory changes characteristic of the acute-phase response, indicating that IL-I
either directly or through other cytokines can activate the complete machinery of this
syndrome [16]. Indeed, IL-I was even found to promote sleep [23].
Rabbits spend about 45-50 percent of daylight hours in NREMS and about 5-10
percent ofthe time in REMS (Fig. 1). When they are given IL-1, either intravenously
or intracerebroventricularly (icv), the amount of time spent in NREMS increases to
60-70 percent or more [23]. The enhancement of NREMS occurs at the expense of
both REMS and wakefulness (Fig. 1) [24]. These effects on sleep are observed within
the first hour after administration of IL-1; in contrast, the increases in sleep after
muramyl peptide (MP) administration appear only after a delay of one to two hours.
IL-I-enhanced NREMS persists for three to 12 hours, depending on the dose. The
animals continue to awaken spontaneously and maintain normal postures; thus, the
excess NREMS seems tobephysiologically normal. AnothercharacteristicofNREMS
induced by IL-I is that it appears to be moreintense than spontaneous sleep; EEG slow
waves (0.5-4.0 Hz) of supranormal amplitudes are observed [23,24]. Similarly, the
deep sleep that follows sleep deprivation is also characterized by EEG slow waves of
very high amplitude [25]: these supranormal EEG slow waves are thought to be a
measure of the intensity (or depth) of NREMS [26]. Thus, after either sleep
deprivation or IL-I treatment, enhanced NREMS seems to result from anexaggerated
activation ofphysiological sleep mechanisms.
The term IL-I refers to two polypeptides distinguished as IL-Ia and IL-I1,, which
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FIG. 1. Effects of intracerebroven-
tricular injection of 5 ng interleukin 1B
(IL-1I#) on rabbit brain temperature
(Tbr), non-rapid-eye-movement sleep
(NREMS), and rapid-eye-movement
sleep (REMS). Values are means ± SE
for six animals (except Tbr, n = 5).
Symbols are as follows: control re-
cordings (artificial cerebrospinal fluid.
TIME POSTINJECTION (h) open circles), IL--v-(closed circles).
identical biological actions when studied in various in vitro and in vivo tests [27]. The
sleep effects ofIL-Ia and IL-1,B are also very similar [28]. Increases in NREMS were
also observed after administration oftwoother cytokines, tumor necrosis factor (TNF)
[24] and interferon a2 (IFNa2) [29]. The somnogenic actions of these cytokines could
be mediated through IL-1 (both TNF [30] and IFN can release IL-1, though this
effect of IFNa2 is relatively weak [31]), or they could act independent of IL-1. TNF,
for example, is known to share many of the biological actions of IL-1, although the
cellular receptors for TNF and IL-1 (a or ,B) are different [32]. Similarly, the
pyrogenic action ofIFN is probably not mediated through IL-I [33].
In considering the sleep-promoting effects of cytokines, particularly IL-1, our
starting point was a pathological condition: the acute-phase response. When IL-I is
injected into an animal, increased sleep appears as part of the acute-phase response,
accompanied by other symptoms like fever, elevated serum copper, and so on [16]. It is
therefore important to determine whether the IL-I mediation of sleep only functions
under special conditions or also contributes to normal sleep regulation. Theoretical
considerations and indirect evidence suggest that IL- I can be involved in physiological
sleep regulation [34].
It is reasonable to suppose that the various aspects of the acute-phase response are
mediated at different sites and therefore can be separated. Thus, antipyretics inhibit
IL-i-induced fever without attenuating the increases in NREMS [23]. Interleukin 6
(IL-6), a recently discovered cytokine, has been implicated in the mediation ofcertain
IL-1 effects, such as synthesis of acute-phase proteins and fever [35]; icv administra-
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FIG. 2. Effects of intracerebroven-
tricular injection of 80 ng interleukin 6
(IL-6) on rabbit brain temperature
(TbO), non-rapid-eye-movement sleep
(NREMS), and rapid-eye-movement
sleep (REMS). Values are means ± SE
for six animals (except Tbr, n = 5).
Symbols are as follows: control record-
ings (artificial cerebrospinal fluid, open
circles), IL-6 (closedcircles).
increased sleep (Fig. 2) [36]. It has been suggested, therefore, that endogenous IL-I
released in optimal concentrations at the proper effector site(s) may promote sleep
without evoking the complete pattern ofthe acute-phase response [34].
Various cells can produce IL-1; however, macrophages are the primary source of
blood-borne IL-1, which mediates various symptoms of the acute-phase response.
Although plasma IL-I activity reportedly peaks at the onsetofNREMS in man [37], it
is likely that IL- I involved in physiological sleep regulation is ofCNS origin. IL-I-like
activity in the CSFvaries with thesleep-wake cycle [38]. Receptors for IL-I have been
demonstrated in various structures in the CNS [39]. IL-1,B mRNA is constituently
expressed in the brain [40]; glial cells are known to produce IL-1 [41]. Recently,
IL-1-immunoreactive hypothalamic neurons were described [42]. These findings
clearly indicate that IL-1 is not only a mediator of the acute-phase response but has
physiological functions in the CNS.
MULTIPLE SLEEP FACTORS: A SLEEP ACTIVATIONAL SYSTEM
Based on various considerations, including their sleep-promoting effects, a great
number of substances have been proposed as physiological SFs. Table 1 provides a
summary of putative SFs. Note, however, that this list is probably far from complete.
None ofthese substances arespecific for sleep; most ofthem are well-known neuropep-
tides, transmitters, hormones, or immunomodulators. As a result of testing in various
in vitro and in vivo systems, these substances have also been shown to interact; they














Substances That Have Been Identified as Sleep Factors
References
A. Substances that enhance non-rapid-eye-movement sleep (NREMS):
cholecystokinin (CCK) [43,44]
insulin [45,46]
desacetyl-alpha-melanocyte-stimulating hormone (desacetyl-a-MSH) [47]
interleukin 1 (IL-1) [23,24]
interferon a2 (IFNa2) [29]
tumor necrosis factor (TNF) [24]
muramyl peptides (MPs) [8,9]
double-stranded RNA (dsRNA) [14,15]
endotoxin/lipid A [12,13]
B. Substances that enhance REMS:
somatostatin [46,48]
growth hormone (GH) [49-51]
corticotropin-like intermediate lobe peptide (CLIP) [47]
vasoactive intestinal polypeptide (VIP) [52-56]
peptide histidine-isoleucine (PHI) [56]
prolactin (PRL) [56,57]
gamma-Br [58]
C. Substances that enhance both NREMS and REMS:
growth hormone-releasing factor (GRF) [59-62]
delta sleep-inducing peptide (DSIP) [63-65]
arginine vasotocin (AVT) [66,67]




D. Substances that inhibit sleep:
a-MSH/adrenocorticotropic hormone (ACTH) [73,74]
corticotropin-releasing factor (CRF) [59,75]
endogenous opioids [76]
glucocorticoids [77]
thyrotropin-releasing hormone (TRH) [78]
prostaglandin E2 (PGE2) [69,79]
neuropeptide Y [80]
substances are in fact SFs, the interaction between them can be regarded as sleep
regulation itself. We call the SFs linked through their interactions the sleep activa-
tional system. In this model, sleep is regulated through cascades ofbiochemical events;
however, many ofthe pathways can also work in relative independence, and a wealth of
feedback loops is involved. It is important to emphasize that at present we do not know
the relative contribution ofthe individual substances to physiological sleep regulation.
Furthermore, the interactions are derived from experiments in which sleep was not
monitored; therefore, the role of these interactions in sleep regulation remains to be
evaluated. With these considerations in mind, a part ofthe sleep activational system is
depicted in Fig. 3; there is reasonable evidence to suppose that the substances and
interactions shown are involved in sleep regulation [81,82].
Stimuli associated with duration of prior wakefulness and the circadian clock are
generally assumed to be inputs for sleep regulation [26]. Although tissue fluid levels of
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FIG. 3. Sleep activational system showing possible interaction between putative sleep factors and effects
ofthose sleep factors on non-rapid-eye-movement sleep (NREMS) and rapid-eye-movement sleep (REMS).
The usefulness of this model is that it provides concrete examples for testing experimentally. For example,
one would predict that during bacterial infection, when the supply of MPs and/or LPS is increased, that
NREMS should be enhanced because cytokine production is enhanced; this hypothesis, indeed, seems to be
the case (see [18,19]). Another prediction, not yet tested, would be that ifone lesioned the arcuate nucleus,
thereby removing neurons containing CRF and alpha MSH, one would remove a negative feedback signal
for IL-1: this procedure should result in a "right shifted" IL-1 dose-sleep response curve. dsRNA,
double-stranded ribonucleic acid; LPS, lipopolysaccharide; MPs, muramyl peptides; 5HT, serotonin; TNF,
tumor necrosis factor; IFN, interferon; IL-1, interleukin 1; PG, prostaglandin; CRF, corticotropin-releasing
factor; POMC, proopiomelanocorticotropin; ACTH, adrenocorticotropic hormone; a-MSH, alpha melano-
cyte-stimulating hormone; CLIP, corticotropin-like intermediate lobe peptide; DSIP, delta sleep-inducing
peptide; GRF, growthhormone-releasing factor; GH,growth hormone; SOM, somatostatin; CCK, cholecys-
tokinin; PHI, peptide histidine isoleucine; VIP, vasoactive intestinal peptide; PRL, prolactin. Refer to
Table 1 for original references concerning the sleep effects ofthese compounds. Left, lines; - indicates
stimulation and q indicates inhibition. Arrows, right, indicatesleepeffects: t indicates increases, I decreases,
- no effect.
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most of the substances depicted in Fig. 3 have circadian rhythms, the mechanisms
responsible for these variations are not known. The effect of normal wakefulness on the
turnover and release of SFs has not been studied, although the effects of sleep
deprivation were tested on some of the substances. Sleep deprivation, however, is not a
physiological condition; many functions might be affected by this stressor, and the
specificity of the changes observed is difficult to determine. IL-I activity in blood [83]
and vasoactive intestinal peptide (VIP) immunoreactivity in the CSF [84] increase
during sleep deprivation. GH secretion is inhibited during sleep deprivation, whereas
recovery sleep is accompanied by greater GH release than normal [85-87]. This
finding may indicate an activation of the hypothalamo-pituitary growth hormone-
releasing factor (GRF)-GH axis. It is likely, however, that both wakefulness and the
circadian clock act on many sites ofthe sleep activational system.
The body is continuously exposed to bacterial invasion from mucous surfaces,
especially from the gut. Bacterial products may therefore have tonic stimulatory
activity on the sleep activational system and may be of primary importance as inputs
for sleep in infectious diseases [2]. As mentioned above, muramyl peptides from
bacteria and endotoxin from gram-negative bacteria stimulate the release ofcytokines.
IL-I and other cytokines, in turn, stimulate the prostaglandin (PG) metabolism
[16,88]. Some PGs, e.g., PGD2, enhance sleep [68], while others, e.g., PGE2 [79],
inhibit sleep; thus it is possible that IL-1 and/or other cytokines alter sleep through
their effects on PGs. Furthermore, PGE2 inhibits IL-1 production and induces IL-1
receptor synthesis [89], thereby providing a somewhat complicated short-loop feed-
back system. The timing of these events in vivo remains unknown.
Association of NREMS and GH secretion has been documented in several species
[90-92], suggesting a link between the two phenomena. It has recently been shown that
icv administration of GRF, a hypothalamic peptide that stimulates pituitary GH
secretion, also promotes sleep, especially NREMS [59-62]. GRF therefore is another
probable input for sleep regulation, and the various stimuli which affect GRF release
all possibly modulate sleep-wake activity. GRF may also be involved in IL-I effects.
IL-1 increases GH secretion through a hypothalamic effector(s) [93] that is (are)
likely to be GRF. Although promotion of sleep and stimulation of GH secretion are
regarded as two separate outputs of the hypothalamic GRF mechanism [62] (the
actions on sleep are assumed to be mediated through basal forebrain projections of the
GRF-containing neurons), the hormonal effects of GRF might contribute to sleep
regulation. GH may provide negative feedback for NREMS [50], and there are
indications that both GH [49-51] and somatostatin [48] (a hypothalamic factor
inhibiting GH secretion; somatostatin release is stimulated by rising GH secretion and
also by GRF) may promote REMS. VIP and peptide histidine-isoleucine (PHI) are
CNS neuropeptides, and, among other functions, they act as hypothalamic releasing
factors for pituitary prolactin secretion [94]. VIP, PHI, and prolactin all stimulate
REMS [52-57]. Although IL-1 stimulates prolactin release via the hypothalamus
[93], it inhibits prolactin secretion from the pituitary [95]. This latter mechanism
might be involved in suppression of REMS after high doses of IL- 1.
The function of the corticotropin-releasing factor (CRF)-adrenocorticotropic hor-
mone (ACTH)-glucocorticoids hypothalamo-pituitary adrenal axis is largely under
circadian control, independent of sleep-wake activity; however, sleep-related inhibition
of this system can also be demonstrated for a short period after sleep onset [96,97].
CRF and ACTH-alpha-melanocyte-stimulating hormone (a-MSH), in turn, inhibit
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sleep [59,73-75], and CRF also inhibits GH secretion in rats through a hypothalamic
mechanism [98]. The CRF-ACTH/a-MSH-glucocorticoid system is likely to act as a
major feedback loop for IL-1 [99]. Hypothalamic CRF secretion is stimulated by IL-I
[100,101]. CRF attenuates IL-1-induced enhancement of NREMS (and fever) [75];
the effects may be mediated, at least in part, by stimulation of central opiomelano-
cortinergic neurons resulting in a-MSH release. Activation ofpituitary ACTH secre-
tion results in glucocorticoid release. Glucocorticoids inhibit IL-1 production and
various IL-I actions [99], though IL-I receptor synthesis is enhanced [89].
Stability is a major characteristic of the proposed sleep activational system. This
feature stems from the multiplicity of SFs, the wealth of sleep-promoting pathways
which often act in parallel, providing alternative mechanisms, and from the numerous
feedback loops. In such a system, manipulation of a single SF is not detrimental,
though the extent of changes may vary with the importance of the factor involved.
Therefore, removal ofa SF or blockade ofa part ofthe sleep activational system per se
does not necessarily result in sleep loss (and certainly not in total insomnia), but rather
in decreased sleep stability. Because of the reduced stability, however, the system
becomes vulnerable; forexample, exogenous orendogenous stimuli which are normally
ineffective may produce impairment of sleep. For example, increased sensitivity to
environmental stimuli is a frequent complaint of patients suffering from sleep distur-
bances.
Due to the stability ofsleep regulation, manipulation of a single SF does not have a
great influence on sleep. In fact, all the experimental manipulations that reliably
produce increases in sleep, i.e., prolonged sleep deprivation, infectious disease, exces-
sive exercise, and prolonged starvation, are not physiologic. In these cases, enhance-
ment of sleep is likely to be mediated at various sites of action. After less aggressive
sleep-promoting manipulations (slight acute increases in ambient temperature above
thermoneutrality, food intake), the occurrence of sleep is a statistical rather than an
obligate phenomenon, indicating that these stimuli affect the sleep activational system
within normal circadian limits.
The effects ofmany ofthe putative SFs vary when tested under different experimen-
tal conditions (species, timing of the administration with respect to the circadian
rhythm, habituation of the animals, and so on) [102]. The variation of the sleep-
promoting actions ofthesesubstances might also result from thestabilityofthesystem.
The effects ofa sleep substance depend on the function, availability, and simultaneous
actions of many other substances, and if all conditions are not met, the exogenous
administration ofa sleep factor might be ineffective. As discussed above, the circadian
pacemaker provides input(s) to the sleep activational system and is therefore an
important stabilizing factor. It has been recognized that some of the proposed SFs
(uridine, PGD2) are more effective when administered during the active cycle than in
the rest cycle [102]. It is assumed that the exogenously applied substance competes
with a high concentration ofendogenously produced SFs for the same receptors in the
rest period, whereas the majority of the receptors are free and available for the
exogenous substance in the active cycle. Other SFs, like delta sleep-inducing factor
(DSIP), seem to be more effective ifthere already exists a spontaneous sleep pressure,
presumably because their actions require prior activation of some component of the
sleep regulation system [103]. Since the CRF-ACTH-glucocorticoid axis is a negative
feedback mechanism for the sleep-promoting and pyrogenic actions ofcytokines, it is
possible that the effects of exogenous IL-1 are attenuated when the endogenous
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corticoid level is high. Indeed, although circadian variations in rabbits are relatively
small, we found that the sleep-promoting effect of MP was slightly reduced (the
pyrogenic action was blocked) when the substance was injected at night [104]. Finally,
if the mechanism of the circadian regulation is a stabilizing factor for the sleep
activational system, it can be assumed that attenuation or removal of this factor
increases the responsiveness ofsleep regulation to exogenous stimuli. In this context, it
is worth noting that many of the putative sleep substances (GRF, DSIP, IL-1, MPs)
are more effective in rabbitswith littlecircadian rhythmthan in rats with a pronounced
circadian variation (e.g., [62]).
MEDIATION OF SPECIFIC SLEEP RESPONSES BY NONSPECIFIC
SUBSTANCES
The sleep activational system illustrated in Fig. 3 shows possible interactions
between many SFs. All of the putative SFs included have other biological activities,
however, some of which are not associated with normal sleep. For example, IL-1 and
some PGs are pyrogenic, yet body temperatures decrease upon entry into NREMS
[105,106]. How can substances not specific to sleep mediatespecific sleep responses?
Electrical or chemical stimulation ofmany brain structures elicits sleep or sleep-like
EEG activity. Lesions in various brain regions result in hypersomnia or insomnia,
followed by partial or complete recovery of sleep. Furthermore, sleep itself involves
changes in many behavioral, psychological, and physiological variables. These vari-
ables, in turn, probably alter the activity of many brain areas implicated in sleep
regulation. Such considerations led McGinty to conclude that sleep is regulated via
numerous independent neuronal networks at all levels ofthe neuraxis [107]. Figure 4
depicts three such neuronal sets (A-C), each contributing to a propensity to sleep,
operating in parallel and interconnecting with each other [81]. Any substance acting
on these neuronal sets to alter sleep/wake activity is considered a SF (W-Z, Fig. 4).
We envision that a single neuronal set will interact with one or more SFs (two in the
case of Fig. 4) and that the magnitude of stimulation of a neuronal set is dependent
upon the concentrations of the SFs interacting with it. Similarly, a single SF may
interact with more than one neuronal set with various affinities, and the effects ofa SF
on one neuronal set maydiffer from its effects on another neuronal set. For the purpose
of illustration, we have assigned hypothetical numerical values to the outputs of each
neuronal set in terms of two different biological activities. These values represent
relative contributions of individual neuronal sets to the variable shown. It is empha-
sized that ifone chooses different neuronal sets, the relevant biological variables would
be different; e.g., another neuronal set may influence sleep, osmotic balance, and blood
glucose levels. It is assumed that if the combined value of the outputs from the three
neuronal sets shown for ain individual activity reaches 9, then an increase in that
activity will occur.' The output from any individual neuronal set is variable, although
limited to the range shown, and depends on the degree of SF stimulation. Thus, the
effect ofSFs on sleep can be described as follows.
'This model is formally set up as a threshold system; i.e., a certain level of activation must be reached
before effects are observed. This method was used for ease of illustration. Similar models in which each
neuronal set continuously provides some degree of activation/inhibition for each biological activity that it
affects can also be constructed. The same conclusions are reached, although the quantitative description of
the process is more lengthy and is unnecessary for this discussion.
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HYPOTHETICAL OUTPUT RANGES FOR INCREASING
SLEEP NEURONAL NREMS BODY
FACTORS SETS PROPENSITY TEMPERATURE
tA - * 1 -6 1- 3
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y
FIG. 4. Illustration of
1111111- 1 - 2 1 - 6 how sleepfactorswith multi-
ple biological activities may
selectively altersleep.
1. Some neuronal sets contribute more (have a largeroutput value; e.g., Fig. 4, A,
B > C) to sleep propensity than others; thus, some SFs are more important for
normal sleep than others (e.g., SF-X has a greater potential for enhancing
sleep than does SF-Z, Fig. 4).
2. If the output of two neuronal sets remains constant, maximal stimulation ofa
third neuronal set could permit the sleep threshold to be reached; that is, the
exogenous administration ofa SF may induce excess sleep.
3. In contrast, ifsets B and C are at minimal output levels, maximal stimulation
ofset A alone will not initiate sleep.
4. Total sleep propensity would bereduced ifonesetwerelesioned, although sleep
would be possible if the remaining sets were driven to a greater degree. Thus,
an inherent feature ofthis model is that noindividual neuronal setcauses sleep,
but all individual sets contribute to overall sleep propensity.
Another concept depicted in Fig. 4 is that neuronal sets are involved in physiological
functions other than sleep. To illustrate how responses specific to sleep could result
from such a construction, we have included one additional physiological parameter in
Fig. 4, body temperature, and, as in the case ofsleep propensity, assigned hypothetical
numerical values for the outputs from each neuronal set for that function. Again, we
assume that a collective value of 9 (from all three sets) must be reached before an
increase in body temperature occurs. If the concentrations of SFs W-Z are such that
the output for A is 6, for B, 2, and for C, 1, then the combined outputs ofsets A-C for
sleep would be 9, thus increasing sleep propensity. In contrast, the combined outputs
for body temperature would be 6 (because neural set A cannot contribute more than 3
to this activity); thus, body temperature would not be affected by this particular
combination ofSFconcentrations; thereby a specific effect on sleep would be observed.
In contrast, if we choose a scenario such that the concentrations of SFs permit an
output of3 forA, 1 for B, and 5 forC, then thecombined outputs fromthethreesetsfor
sleep would be 6, and that for body temperature 9. Thus, body temperature, but not
sleep, would be enhanced under this particular combination ofSF concentrations.
The data presented in Figs. 1 and 2 can be used as concrete examples to illustrate
these ideas further. Thus, IL-1,8 (Fig. 1) may be considered sleep factor X (Fig. 4)
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having the ability to interact strongly with both neuronal sets A and B to enhance
NREMS propensity and also to interact with these sets to enhance body temperature.
In contrast, IL-6 (Fig. 2) may be considered to be an additional factor (not illustrated
and not a sleep factor in Fig. 4) that has thecapacity to increase theoutput ofneuronal
set C for body temperature and, perhaps, other neuronal sets involved in temperature,
but not sleep, regulation. It could not add significantly to NREMS propensity because
it cannot interact with neuronal sets A and B and neuronal set C has only a limited
capacity to alter NREMS.
It is possible that there are multiple sites in the brain hierarchically arranged to
regulate sleep. At each level, something similar to Fig. 4 could be developed; however,
the complexity may be different at each level of the hierarchy. At some levels, it is
possible that no set would be specific for any physiological function, such as sleep, and
all would be involved in regulation oftwo or more variables. We consider such a brain
construction likely for any behavior as complex as sleep.
CONCLUSION
From the discussions presented here, it is clear that cytokines and many other
substances alter sleep. We have presented a model ofhow the regulation of many SFs
may be interrelated and another model illustrating how SFs may interact with various
neuronal sets to produce specific sleep responses. Ten years ago, it would have been
unrealistic topresent such models becausethe rosterofputative SFs was muchsmaller,
and there was very little information concerning how SFs might affect each other;
however, despite the great number ofadvances within the field ofSFs, many questions
remain unanswered. Major challenges that need to be addressed include: (1) How do
SF concentrations change with sleep/wake cycles and under pathological conditions?
(2) What is the timing ofthese changes? (3) Where do thesechanges take place? (4) Is
one change linked directly toanother?
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